Latest news with #Baxter
Yahoo
6 hours ago
- Business
- Yahoo
Vizient Reserve Program Expands Supply Assurance to Include IV Fluids in Collaboration With Baxter
IRVING, Texas, July 23, 2025--(BUSINESS WIRE)--Vizient® announced today the expansion of the Vizient Reserve Program to include IV fluids through a strategic partnership with Baxter, a leading global medtech company, to help ensure reliable access to these critical products during times of supply disruption. The program provides participating healthcare organizations with dedicated, on-demand manufacturer inventory, warehoused in the U.S., along with comprehensive support to help safeguard continuity of care. The expansion of Vizient Reserve to include IV fluids reflects a strategic collaboration with Baxter to improve supply assurance within the healthcare supply chain and comes less than a year after Hurricane Helene hit the east coast, temporarily disrupting supply of this critical product. IV fluids—a uniquely complex category due to their essential nature, high utilization, and complex manufacturing requirements—are foundational to patient care. While Baxter's U.S. IV fluids production levels have been restored since the hurricane, the partnership between Vizient and Baxter reflects a deliberate, long-term strategy to promote resiliency and help healthcare providers prepare for and manage the pressures that natural disasters and increased demand have put on the supply of this critical healthcare category. "IV fluids are among the most relied upon therapies in healthcare. We've created a scalable, cost-effective reserve model that enhances resiliency and transparency across the supply chain," said Dan Kistner, senior vice president and general manager, category management & strategic programs, Vizient. "This approach builds on the success of our NES Reserve program in the pharmaceutical space, further demonstrating how Vizient is rethinking traditional sourcing strategies with proactive, purpose-built solutions designed to mitigate supply disruptions and ensure continuity of care." With comprehensive inventory management, transparent reporting and dedicated logistics, the program offers a flexible structure to enable access during supply disruptions and support continuity of care. "At Baxter, we are actively committed to supporting hospitals and health systems navigate any threat to supply continuity," said Cecilia Soriano, global president of Baxter's infusion therapies and technologies business. "Baxter and Vizient's shared commitment to enabling access to life-sustaining therapies is at the heart of this initiative, and we're honored to support Vizient clients in their efforts to build greater supply resilience." The new program builds on the success of Vizient Novaplus Enhanced Supply (NES) Reserve, which provides up to six months of additional dedicated manufacturer inventory for essential medications, and expands the breadth of products available through it—including the first-ever medical-surgery product codes. Since its inception, NES Reserve has fulfilled more than 45,000 requests from over 1,700 facilities, totaling more than 5 million additional units of essential medications. Learn more about IV fluids in the Vizient Reserve Program. About Vizient, Inc. Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at View source version on Contacts Media ContactNancy Matocha(972)
Business Wire
6 hours ago
- Business
- Business Wire
Vizient Reserve Program Expands Supply Assurance to Include IV Fluids in Collaboration With Baxter
IRVING, Texas--(BUSINESS WIRE)-- Vizient ® announced today the expansion of the Vizient Reserve Program to include IV fluids through a strategic partnership with Baxter, a leading global medtech company, to help ensure reliable access to these critical products during times of supply disruption. The program provides participating healthcare organizations with dedicated, on-demand manufacturer inventory, warehoused in the U.S., along with comprehensive support to help safeguard continuity of care. The expansion of Vizient Reserve to include IV fluids reflects a strategic collaboration with Baxter to improve supply assurance within the healthcare supply chain and comes less than a year after Hurricane Helene hit the east coast, temporarily disrupting supply of this critical product. IV fluids—a uniquely complex category due to their essential nature, high utilization, and complex manufacturing requirements—are foundational to patient care. While Baxter's U.S. IV fluids production levels have been restored since the hurricane, the partnership between Vizient and Baxter reflects a deliberate, long-term strategy to promote resiliency and help healthcare providers prepare for and manage the pressures that natural disasters and increased demand have put on the supply of this critical healthcare category. 'IV fluids are among the most relied upon therapies in healthcare. We've created a scalable, cost-effective reserve model that enhances resiliency and transparency across the supply chain,' said Dan Kistner, senior vice president and general manager, category management & strategic programs, Vizient. 'This approach builds on the success of our NES Reserve program in the pharmaceutical space, further demonstrating how Vizient is rethinking traditional sourcing strategies with proactive, purpose-built solutions designed to mitigate supply disruptions and ensure continuity of care.' With comprehensive inventory management, transparent reporting and dedicated logistics, the program offers a flexible structure to enable access during supply disruptions and support continuity of care. 'At Baxter, we are actively committed to supporting hospitals and health systems navigate any threat to supply continuity,' said Cecilia Soriano, global president of Baxter's infusion therapies and technologies business. 'Baxter and Vizient's shared commitment to enabling access to life-sustaining therapies is at the heart of this initiative, and we're honored to support Vizient clients in their efforts to build greater supply resilience.' The new program builds on the success of Vizient Novaplus Enhanced Supply (NES) Reserve, which provides up to six months of additional dedicated manufacturer inventory for essential medications, and expands the breadth of products available through it—including the first-ever medical-surgery product codes. Since its inception, NES Reserve has fulfilled more than 45,000 requests from over 1,700 facilities, totaling more than 5 million additional units of essential medications. Learn more about IV fluids in the Vizient Reserve Program. About Vizient, Inc. Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at
Irish Daily Mirror
2 days ago
- Irish Daily Mirror
Father jailed for sexually assaulting young daughter weekly over 5-year period
A Kildare father who sexually assaulted his young daughter in her bedroom several nights a week over a period of over five years has been sentenced to five and a half years in prison. The separated father of three was convicted of 22 counts of sexual assault on his daughter following a four-day trial at Naas Circuit Criminal Court last March. The 55-year-old businessman, who cannot be named to protect his victim's identity, had denied all charges and continues to reject the jury's verdicts. At a sentencing hearing on Monday, Judge Martina Baxter noted that the charges were sample counts spread out on a quarterly basis over the duration of the offending, which took place in the victim's bedroom in her family home. The judge claimed there had been 'a monumental breach of trust' by the accused. 'The role of a Dad is to protect his daughter from harm,' Judge Baxter remarked. 'She was supposed to be in a safe place but there was a violation of her space and her bodily integrity.' She claimed his actions on a young vulnerable child, who was completely blameless, had a profound and life-changing impact on her. The court heard the offences first began in July 2015 and continued until September 2020 over a period when the girl was aged approximately 6-11 years old. Judge Baxter observed that many of the charges occurred at a time when the defendant's marriage to the victim's mother was breaking down when he would sleep on a lower bunk bed with his daughter in her bedroom. The court heard the accused had also taken legal proceedings to try and prevent his wife and their children moving to another part of the country following the ending of their marriage. Evidence was previously heard that the girl, who is now aged 15, first reported what had happened in May 2022, which resulted in her father being arrested 12 months later. The accused denied all the allegations against him when questioned by Gardaí and maintained his innocence. While he did not believe his daughter was maliciously lying about being sexually assaulted by him, he told Gardaí he felt she had been affected by the separation of her parents. During interviews with specialists, the girl outlined how her father would sexually assault her two to three times every week. She described how he would sleep naked next to her and form a C-position around her so that she could feel the lower part of his body like it was 'jumping' into her. The court heard that he would rub his penis against her private parts for up to 15 minutes although there was no penetration. The girl said she never said anything back to her father but recalled how it made her feel uncomfortable. The Irish Mirror's Crime Writers Michael O'Toole and Paul Healy are writing a new weekly newsletter called Crime Ireland. Click here to sign up and get it delivered to your inbox every week She particularly remembered one night when he placed his hand over her mouth and told her to shush when her brother was heard getting up to go to the bathroom. Judge Baxter observed that the girl, who completed her Junior Certificate this year, has provided a thoughtful and impactful victim impact statement. The judge said she had clearly been traumatised by what was done to her by someone she adored and trusted but was making an encouraging recovery after the ending of her parents' marriage. 'You are a brave, courageous and insightful young woman,' the judge told the girl, who was accompanied to court by her mother and siblings. Sentencing the accused to five and a half years imprisonment, Judge Baxter also ordered that he be subject to two years supervision on his release from prison and noted he was now a registered sex offender. The judge said she could provide no mitigation as the defendant had demonstrated no element of insight or prospect of rehabilitation. Addressing the accused, she said there was no doubt that he had lost everything in what had previously been an unblemished career. The court heard he had no previous criminal convictions. The man shook hands with a number of people in the courtroom before being led away by prison officers. Subscribe to our newsletter for the latest news from the Irish Mirror direct to your inbox: Sign up here.
Yahoo
2 days ago
- Business
- Yahoo
3 Reasons to Avoid BAX and 1 Stock to Buy Instead
Over the past six months, Baxter's shares (currently trading at $27.77) have posted a disappointing 11.8% loss, well below the S&P 500's 4.1% gain. This may have investors wondering how to approach the situation. Is now the time to buy Baxter, or should you be careful about including it in your portfolio? Get the full breakdown from our expert analysts, it's free. Why Do We Think Baxter Will Underperform? Even though the stock has become cheaper, we're sitting this one out for now. Here are three reasons why BAX doesn't excite us and a stock we'd rather own. 1. Revenue Spiraling Downwards A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Baxter struggled to consistently generate demand over the last five years as its sales dropped at a 1.3% annual rate. This wasn't a great result and is a sign of poor business quality. 2. Weak Constant Currency Growth Points to Soft Demand Investors interested in Medical Devices & Supplies - Diversified companies should track constant currency revenue in addition to reported revenue. This metric excludes currency movements, which are outside of Baxter's control and are not indicative of underlying demand. Over the last two years, Baxter's constant currency revenue averaged 4.1% year-on-year growth. This performance slightly lagged the sector and suggests it might have to lower prices or invest in product improvements to accelerate growth, factors that can hinder near-term profitability. 3. EPS Trending Down Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. Sadly for Baxter, its EPS declined by 4.7% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand. Final Judgment Baxter falls short of our quality standards. After the recent drawdown, the stock trades at 11× forward P/E (or $27.77 per share). This valuation tells us it's a bit of a market darling with a lot of good news priced in - you can find more timely opportunities elsewhere. We'd recommend looking at one of our top software and edge computing picks. Stocks We Like More Than Baxter When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 days ago
- Business
- Business Wire
Baxter to Host Second-Quarter 2025 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2025 financial results on Thursday, July 31, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 38,000 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit and follow us on X, LinkedIn and Facebook.
